Veru (FMW0) AI Stock Analysis

Company Guidance

In the call Veru gave near‑term guidance that its fully enrolled Phase IIb PLATEAU study (239 patients, age ≥65, BMI ≥35) will have an interim analysis of DEXA‑measured lean and fat mass at 32 weeks expected in Q1 2027 and a primary endpoint readout (percent change in total body weight at 68 weeks) by Q4 2027; the program tests enobosarm (Phase IIb QUALITY previously randomized 168 patients age ≥60 to enobosarm 3 mg, 6 mg or placebo on semaglutide) with key secondary endpoints including total fat mass, total lean mass, stair‑climb physical function, mobility disability, bone mineral density, PROMs, HbA1c and insulin resistance. Management said cash, cash equivalents and restricted cash of $23.9M and net working capital of $21.1M as of June 30, 2026 is expected to be sufficient to fund operations beyond the interim analysis; quarterly R&D expense was $4.4M (prior quarter $3.0M), G&A $3.4M (prior $5.0M), net loss $7.0M or $0.30/share (prior $7.3M, $0.50), nine‑month net loss $15.1M or $0.68/share (prior $24.2M, $1.65), cash used in operations $20.6M YTD, cash from investing $5.3M YTD and net cash from financing $23.3M (public offering). They also highlighted a June 2, 2026 supply agreement with Novo Nordisk (Wegovy supplied at no charge), a U.S. patent notice of allowance with expiry at least Oct 3, 2044 (and a potential formulation patent to May 2046), and market context metrics (41.5% obesity prevalence in ≥65s, 47.4M Medicare Part D enrollees ≈20M potential patients, plus clinical context that 88% of GLP‑1 patients hit a 1‑year plateau and 62.6% remained clinically obese in SURMOUNT‑1).